ClinicalTrials.gg
CompletedNCT01197560Updated Nov 25, 2019Results posted

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 2/3 interventional study of Lenalidomide and Gemcitabine in Diffuse Large B-cell Lymphoma, sponsored by Celgene. Completed at 57 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-25.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse — 14 open to participants now, 29 under way, 4 of them phase 3. Lenalidomide · Lymphoma, Large B-Cell, Diffuse.

Enrollment
19th of 70
111 · median 55
Started
2010
with 4 others
Phase 2/3
Only one
of the 71
Registered
13th of 71
by date
Lead sponsor
2 of 71
Celgene

Among the 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse, this one is the 19th largest by enrollment of the 70 interventional ones that give a count, is one of 5 that started in 2010, is the only one in phase 2/3, and was the 13th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

14 of the 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse are open now, in 4 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

The purpose of this study is to compare lenalidomide to a control drug and see which one delays Diffuse Large B-Cell Lymphoma (DLBCL) disease progression longer.

Read the detailed description

This research study is for patients who have been diagnosed with Diffuse Large B-cell Lymphoma (DLBCL) that did not respond to (refractory) or that has come back after chemotherapy treatment (relapsed). Lymphoma is a cancer of a type of blood cell called lymphocytes. DLBCL is just one type of lymphoma. Within DLBCL there are two different subtypes called Germinal Center B-cell (GCB) and non-GCB which can be determined by cell surface marker tests or by gene expression tests. Scientists can look at cells and genes in the laboratory and see that the two kinds are different, but they don't know yet what the difference means. To patients and doctors these two kinds seem the same. Right now doctors don't usually do tests to find out which kind a patient has because the treatment is the same for both.

This study will have two stages, 1 and 2. The main purpose of Stage 1 is to separate patients by subtype and then test whether patients taking lenalidomide or any one of four other drugs have a better response. It is possible that lenalidomide will work better than one of the other drugs in zero, one, or both subtypes. Stage 2 will further test only the subtype(s) from Stage 1 that showed a good response to lenalidomide. The main purpose of Stage 2 is to test how long patients are disease free on lenalidomide compared to one of the four other drugs.

On 29 January 2013 the enrolment goal for the Stage 1 portion of the study was met and enrollment was stopped. The final analysis for Stage 1 was performed as of the 04 Jul 2013 data cutoff date. According to the Stage 1 results as assessed by the independent response adjudication committee (IRAC), neither subtype met the pre specified requirement to be further studied in Stage 2. Additionally, a suitable assay for the selection of participants for the Stage 2 study was not available. Therefore, on 6 January 2014, Celgene decided to not open Stage 2.

03

Conditions studied

  • Diffuse Large B-cell Lymphoma

Keywords

  • Diffuse Large B-Cell Lymphoma
  • Non Hodgkin's Lymphoma
  • relapsed
  • refractory
  • relapsed/refractory
  • DLBCL
  • Diffuse Large B Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven Diffuse Large B-Cell Lymphoma (DLBCL).
  • to combination chemotherapy for DLBCL that contains rituximab and an anthracycline, and one additional combination chemotherapy or stem cell transplant.
  • Measurable DLBCL disease by computed tomograph (CT) / magnetic resonance imagining (MRI).
  • (ECOG) performance status 0 - 2.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of lymphoma histologies other than DLBCL.
  • History of , other than DLBCL, unless the patient has been disease free for 3 years or more.
  • Eligible for stem cell transplant.
  • Known seropositive for, or history of, active (HIV) virus (HBV), virus (HCV)
  • Neuropathy grade 4.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    Lenalidomide

    Lenalidomide 25 mg capsules by mouth on days 1-21 of each 28 day cycle. For patients with Creatinine Clearance ≥ 30 mL/min but \< 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).

    Drug: Lenalidomide

  • Active comparator
    Investigators Choice

    One of the following: Gemcitabine, Oxaliplatin, Rituximab, or Etoposide

    Drug: Gemcitabine · Drug: Oxaliplatin · Drug: Rituximab · Drug: Etoposide

Interventions

  • Lenalidomide 25 mg orally for 21/28 days until Diffuse Large B-Cell Lymphoma (DLBCL) progressive disease. For patients with Creatinine Clearance ≥ 30 mL/min but \< 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).

  • Suggested starting doses and regimens for Gemcitabine is 1,250 mg/m\^2 intravenous (IV) administration on days 1, 8, 15 every 28 days for 6 Cycles or 1,000 mg/m\^2 IV days 1 and 15 every 28 days for 6 Cycles

  • Suggested starting dose and regimen for Oxaliplatin is 100 mg/m\^2 IV day 1 for 21 days for 6 Cycles

  • Suggested starting dose for Rituximab is 375 mg/m\^2 IV days 1, 8, 15, 22 during Cycle 1, and if stable disease at Week 12, also on Day 1 of Cycles 4, 6, 8, and 10 (CD20+ patients only)

  • Suggested starting doses for Etoposide are: 100 mg/m\^2 IV days 1-5 every 28 days for 6 Cycles, or 100 mg/m\^2 IV days 1-3 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-21 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-14 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-10 every 28 days for 6 Cycles

06

What researchers measure

Primary outcomes

  1. Stage 1: Percentage of Participants With an Overall Response According to the International Working Group (IWG) Response Criteria for Non Hodgkin's Lymphoma (NHL), Cheson 1999 and Evaluated by the Independent Response Adjudication Committee (IRAC)

    An overall response is a complete response (CR), unconfirmed complete response (CRu) or partial response (PR) and was evaluated by the IRAC. A CR = complete disappearance of disease and related symptoms. Lymph nodes and nodal masses regressed on computed tomography to normal size (≤ 1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm prior to therapy and ≤ 1.0 cm in their short axis for nodes 1.1-1.5 cm in their long axis and \> 1.0 cm in their short axis prior to therapy). Spleen and/or liver not palpable on exam, normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, infiltrate must have cleared on repeat biopsy. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in other nodes, liver, or spleen. Splenic and hepatic nodules regressed by ≥ 50% in their SPD or for single nodules, in the greatest transverse diameter;no new disease.

    Time frame: From the date of randomization to the data cut-off of 4 July 2013; when all patients reached the scheduled 16-week assessment or had progressed/died before the scheduled 16-week assessment); the median study duration was 27.0 and 19.7 weeks, respectively.

  2. Stage 1: Percentage of Participants With an Overall Response According to the IWG Response Criteria Based on the Investigators Assessment at the Final Data Cut During the Core Treatment Phase

    Response was defined as having a CR, CRu or PR, based on IWG 1999 Response Criteria for NHL as evaluated by the investigators. CR = complete disappearance of disease and disease related symptoms. All lymph nodes and nodal masses regressed on computed tomography to normal size (≤ 1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm prior to therapy and ≤ 1.0 cm in their short axis for nodes 1.1-1.5 cm in their long axis and \> 1.0 cm in their short axis prior to therapy). Spleen and/or liver not palpable on physical exam, normal size by imaging, and absence of nodules related to lymphoma. If BM was involved prior to therapy, infiltrate must have cleared on repeat biopsy. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in the other nodes, liver, or spleen. Splenic and hepatic nodules regressed by ≥ 50% in their SPD or, for single nodules, in the greatest transverse diameter. No new disease.

    Time frame: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.

Secondary outcomes

  1. Number of Participants With Treatment Emergent Events (TEAEs) in the Overall Treatment Phase by Initial Treatment Assignment

    A TEAE was defined as an AE that begins or worsens in intensity of frequency on or after the first dose of study drug through 28 days after last dose of study drug. A serious adverse event (SAE) is any: * Death; * Life-threatening event; * Any inpatient hospitalization or prolongation of existing hospitalization; * Persistent or significant disability or incapacity; * Congenital anomaly or birth defect; * Any other important medical event The investigator determined the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the event.The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.03) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death

    Time frame: From first dose of study drug to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.

  2. Stage 2: Overall Response Rate (ORR)

    ORR is defined as: Complete Response + Complete Response unconfirmed + Partial Response based on the International Lymphoma Workshop Response Criteria \[IWRC\] (Cheson 1999).

    Time frame: Approximately 3.5 years

  3. Stage 2: Duration of Response (DoR)

    Length of time of overall response (Complete Response + Complete Response unconfirmed + Partial Response) based on the International Lymphoma Workshop Response Criteria \[IWRC\] (Cheson 1999).

    Time frame: Approximately 3.5 years

  4. Stage 2: Overall Survival (OS)

    Overall survival was defined as time from randomization until death of any cause.

    Time frame: Approximately 3.5 years

  5. Stage 2: Duration of Complete Response

    Length of time of complete response (Complete Response + Complete Response unconfirmed) based on the International Lymphoma Workshop Response Criteria \[IWRC\] (Cheson 1999).

    Time frame: Approximately 3.5 years

  6. Stage 2: Overall Response Rate for With a Duration of Response Lasting ≥ 16 Weeks

    Complete Response + Complete Response unconfirmed + Partial Response for participants with a duration of response lasting ≥ 16 weeks based on the International Lymphoma Workshop Response Criteria \[IWRC\] (Cheson 1999).

    Time frame: Approximately 3.5 years

  7. Stage 2: Time to Progression

    Length of time until disease progression occurs

    Time frame: Approximately 3.5 years

  8. Stage 2: Health Related Quality of Life Questionnaires

    Quality of Life based on the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and the EQ-5D assessments

    Time frame: Approximately 3.5 years

Other outcomes

  1. Stage 1: Percentage of Participants With a Durable Overall Response (dORR) According to the IWG Response Criteria as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase

    Durable overall response rate was defined as the percentage of participants who maintained a response for at least 16 weeks after initial response.

    Time frame: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.

  2. Stage 1: Percentage of Participants With a Complete Response According to the IWG Response Criteria as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase

    A complete response was defined as participants with a complete response (CR), or unconfirmed complete response (CRu) based on IWG 1999 Response Criteria for NHL as assessed by the investigator. A CR is a complete disappearance of all disease with the exception of nodes. No new lesions. Previously enlarged organs must have regressed and not be palpable. Bone marrow must be negative if positive at baseline. Normalization of markers. CR Unconfirmed (CRu) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM.

    Time frame: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.

  3. Stage 1: Kaplan Meier Estimates of Duration of Overall Response (DoR) as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase

    Duration of overall response was calculated as the time of initial response (CR+CRu+PR) until documented disease progression determinted by computerized scan CT scan or MRI or death due to lymphoma, whichever occurred earlier, for participants who responded.

    Time frame: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.

  4. Stage 1: Kaplan Meier Estimates of Duration of Complete Response (DoCR) as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase

    Duration of complete response was defined as the time from the first documented complete response (CR + CRu) until the first disease progression or death for participants who had a CR.

    Time frame: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.

  5. Stage 1: Kaplan Meier Estimates of Progression-Free Survival As Assessed By The Investigators At The Final Data Cut During The Core Treatment Phase

    Progression-free survival was defined as the time from randomization to the first documented disease progression or death due to any cause.

    Time frame: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.

  6. Stage 1: Kaplan Meier Estimates of Overall Survival As Assessed by the Investigators at the Final Data Cut During The Core Treatment Phase

    Overall survival was defined as time from randomization until death of any cause.

    Time frame: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.

  7. Stage 2: Progression-Free Survival

    Number of participants who survive without progressing based on the International Working Group Response Criteria \[IWG\].

    Time frame: Approximately 3.5 years

07

Results

Posted Aug 20, 2014
Limitations and caveats
On 29 January 2013 the Stage 1 portion of the study was met and enrollment stopped. The Stage 1 results as assessed by the IRAC demonstrated that neither subtype met the prespecified requirement to be further studied in Stage 2.

Participant flow

Screening and enrollment occurred at 43 sites, including 10 in the United States, 9 in France, 7 in the United Kingdom; 4 in Spain, 4 in Italy, 3 each in Austria and Australia, 2 in the Czech Republic, and 1 in Sweden.

Participant flow — Overall Study
MilestoneLenalidomideInvestigators Choice (Control Arm)
Started5457
Received ≥ one dose study drug5455
Lenalidomide crossover029
Discontinued treatment after ≥ 6 cycles140
Completed04
Not completed5453
Withdrew: Adverse event68
Withdrew: Death35
Withdrew: Withdrawal by subject11
Withdrew: Disease progression4035
Withdrew: Miscellaneous43
Withdrew: Missing01

Outcome measures

PrimaryStage 1: Percentage of Participants With an Overall Response According to the International Working Group (IWG) Response Criteria for Non Hodgkin's Lymphoma (NHL), Cheson 1999 and Evaluated by the Independent Response Adjudication Committee (IRAC)

An overall response is a complete response (CR), unconfirmed complete response (CRu) or partial response (PR) and was evaluated by the IRAC. A CR = complete disappearance of disease and related symptoms. Lymph nodes and nodal masses regressed on computed tomography to normal size (≤ 1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm prior to therapy and ≤ 1.0 cm in their short axis for nodes 1.1-1.5 cm in their long axis and \> 1.0 cm in their short axis prior to therapy). Spleen and/or liver not palpable on exam, normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, infiltrate must have cleared on repeat biopsy. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in other nodes, liver, or spleen. Splenic and hepatic nodules regressed by ≥ 50% in their SPD or for single nodules, in the greatest transverse diameter;no new disease.

Time frame:
From the date of randomization to the data cut-off of 4 July 2013; when all patients reached the scheduled 16-week assessment or had progressed/died before the scheduled 16-week assessment); the median study duration was 27.0 and 19.7 weeks, respectively.
Reported as:
Number · percentage of participants
Stage 1: Percentage of Participants With an Overall Response According to the International Working Group (IWG) Response Criteria for Non Hodgkin's Lymphoma (NHL), Cheson 1999 and Evaluated by the Independent Response Adjudication Committee (IRAC)
percentage of participantsLenalidomideInvestigators Choice (IC)
ORR for All Participants27.5 (15.9 to 41.7)11.8 (4.4 to 23.9)
GCB Subtype26.1 (10.2 to 48.4)12.0 (2.5 to 31.2)
Non-GCB28.6 (13.2 to 48.7)11.5 (2.4 to 30.2)
Statistical analysis
  • Lenalidomide vs Investigators Choice (IC) · Fisher Exact · p = 0.079
  • Investigators Choice (IC) · Fisher Exact · p = 0.279
  • Investigators Choice (IC) · Fisher Exact · p = 0.179
PrimaryStage 1: Percentage of Participants With an Overall Response According to the IWG Response Criteria Based on the Investigators Assessment at the Final Data Cut During the Core Treatment Phase

Response was defined as having a CR, CRu or PR, based on IWG 1999 Response Criteria for NHL as evaluated by the investigators. CR = complete disappearance of disease and disease related symptoms. All lymph nodes and nodal masses regressed on computed tomography to normal size (≤ 1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm prior to therapy and ≤ 1.0 cm in their short axis for nodes 1.1-1.5 cm in their long axis and \> 1.0 cm in their short axis prior to therapy). Spleen and/or liver not palpable on physical exam, normal size by imaging, and absence of nodules related to lymphoma. If BM was involved prior to therapy, infiltrate must have cleared on repeat biopsy. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in the other nodes, liver, or spleen. Splenic and hepatic nodules regressed by ≥ 50% in their SPD or, for single nodules, in the greatest transverse diameter. No new disease.

Time frame:
From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
Reported as:
Number · Percentage of participants
Stage 1: Percentage of Participants With an Overall Response According to the IWG Response Criteria Based on the Investigators Assessment at the Final Data Cut During the Core Treatment Phase
Percentage of participantsLenalidomideInvestigators Choice (IC)
Stage 1: Percentage of Participants With an Overall Response According to the IWG Response Criteria Based on the Investigators Assessment at the Final Data Cut During the Core Treatment Phase29.4 (17.5 to 43.8)13.7 (5.7 to 26.3)
Statistical analysis
  • Lenalidomide vs Investigators Choice (IC) · Fisher Exact · p = 0.091
Other pre-specifiedStage 1: Percentage of Participants With a Durable Overall Response (dORR) According to the IWG Response Criteria as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase

Durable overall response rate was defined as the percentage of participants who maintained a response for at least 16 weeks after initial response.

Time frame:
From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
Reported as:
Median · percentage of participants
Stage 1: Percentage of Participants With a Durable Overall Response (dORR) According to the IWG Response Criteria as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase
percentage of participantsLenalidomideInvestigators Choice (Control Arm)
Stage 1: Percentage of Participants With a Durable Overall Response (dORR) According to the IWG Response Criteria as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase23.5 (12.8 to 37.5)9.8 (3.3 to 21.4)
Statistical analysis
  • Lenalidomide vs Investigators Choice (Control Arm) · Fisher Exact · p = 0.109
Other pre-specifiedStage 1: Percentage of Participants With a Complete Response According to the IWG Response Criteria as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase

A complete response was defined as participants with a complete response (CR), or unconfirmed complete response (CRu) based on IWG 1999 Response Criteria for NHL as assessed by the investigator. A CR is a complete disappearance of all disease with the exception of nodes. No new lesions. Previously enlarged organs must have regressed and not be palpable. Bone marrow must be negative if positive at baseline. Normalization of markers. CR Unconfirmed (CRu) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM.

Time frame:
From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
Reported as:
Number · percentage of participants
Stage 1: Percentage of Participants With a Complete Response According to the IWG Response Criteria as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase
percentage of participantsLenalidomideInvestigators Choice (IC)
Stage 1: Percentage of Participants With a Complete Response According to the IWG Response Criteria as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase13.7 (5.7 to 26.3)3.9 (0.5 to 13.5)
Statistical analysis
  • Lenalidomide vs Investigators Choice (IC) · Fisher Exact · p = 0.160
Other pre-specifiedStage 1: Kaplan Meier Estimates of Duration of Overall Response (DoR) as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase

Duration of overall response was calculated as the time of initial response (CR+CRu+PR) until documented disease progression determinted by computerized scan CT scan or MRI or death due to lymphoma, whichever occurred earlier, for participants who responded.

Time frame:
From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
Reported as:
Median · Weeks
Stage 1: Kaplan Meier Estimates of Duration of Overall Response (DoR) as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase
WeeksLenalidomideInvestigators Choice (Control Arm)
Stage 1: Kaplan Meier Estimates of Duration of Overall Response (DoR) as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase64.7 (29.1 to 141.6)63.1 (15.3 to 79.4)
Statistical analysis
  • Lenalidomide vs Investigators Choice (Control Arm) · Log Rank · p = 0.529
Other pre-specifiedStage 1: Kaplan Meier Estimates of Duration of Complete Response (DoCR) as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase

Duration of complete response was defined as the time from the first documented complete response (CR + CRu) until the first disease progression or death for participants who had a CR.

Time frame:
From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
Reported as:
Median · Weeks
Stage 1: Kaplan Meier Estimates of Duration of Complete Response (DoCR) as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase
WeeksLenalidomideInvestigators Choice (Control Arm)
Stage 1: Kaplan Meier Estimates of Duration of Complete Response (DoCR) as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase66.4 (22.1 to NA)179.3 (63.1 to 295.4)
Statistical analysis
  • Lenalidomide vs Investigators Choice (Control Arm) · Log Rank · p = 0.972
Other pre-specifiedStage 1: Kaplan Meier Estimates of Progression-Free Survival As Assessed By The Investigators At The Final Data Cut During The Core Treatment Phase

Progression-free survival was defined as the time from randomization to the first documented disease progression or death due to any cause.

Time frame:
From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
Reported as:
Median · Weeks
Stage 1: Kaplan Meier Estimates of Progression-Free Survival As Assessed By The Investigators At The Final Data Cut During The Core Treatment Phase
WeeksLenalidomideInvestigators Choice (IC)
Stage 1: Kaplan Meier Estimates of Progression-Free Survival As Assessed By The Investigators At The Final Data Cut During The Core Treatment Phase9.6 (7.6 to 17.1)7.1 (6.0 to 8.3)
Statistical analysis
  • Lenalidomide vs Investigators Choice (IC) · Log Rank · p = 0.020
Other pre-specifiedStage 1: Kaplan Meier Estimates of Overall Survival As Assessed by the Investigators at the Final Data Cut During The Core Treatment Phase

Overall survival was defined as time from randomization until death of any cause.

Time frame:
From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
Reported as:
Median · Weeks
Stage 1: Kaplan Meier Estimates of Overall Survival As Assessed by the Investigators at the Final Data Cut During The Core Treatment Phase
WeeksLenalidomideInvestigators Choice (IC)
Stage 1: Kaplan Meier Estimates of Overall Survival As Assessed by the Investigators at the Final Data Cut During The Core Treatment Phase31.0 (16.6 to 43.7)24.6 (12.7 to 34.9)
Statistical analysis
  • Lenalidomide vs Investigators Choice (IC) · Log Rank · p = 0.211
SecondaryNumber of Participants With Treatment Emergent Events (TEAEs) in the Overall Treatment Phase by Initial Treatment Assignment

A TEAE was defined as an AE that begins or worsens in intensity of frequency on or after the first dose of study drug through 28 days after last dose of study drug. A serious adverse event (SAE) is any: * Death; * Life-threatening event; * Any inpatient hospitalization or prolongation of existing hospitalization; * Persistent or significant disability or incapacity; * Congenital anomaly or birth defect; * Any other important medical event The investigator determined the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the event.The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.03) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death

Time frame:
From first dose of study drug to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Events (TEAEs) in the Overall Treatment Phase by Initial Treatment Assignment
ParticipantsLenalidomideInvestigators Choice (IC)
Any TEAEs5455
Any Treatment Related TEAE4945
Any TEAE Grade ≥ 34353
Any TEAE Grade ≥ 42936
Any TEAE Grade 5918
Any TEAE Grade 3 or 44252
Any Treatment Related TEAE Grade ≥ 33039
Any Treatment Related TEAEs Grade ≥ 41521
Any Treatment Related TEAE Grade 502
Any Treatment Related TEAE Grade 3 or 43039
Any Serious Adverse Events (SAEs)3142
Any Treated Related SAEs1421
Any AE leading to stopping of study drug1117
Any drug related AE leading to halt of study drug54
Any AE leading to dose interruption/reduct3234
Any drug related AE leading to interruption/reduct2730
SecondaryStage 2: Overall Response Rate (ORR)

ORR is defined as: Complete Response + Complete Response unconfirmed + Partial Response based on the International Lymphoma Workshop Response Criteria \[IWRC\] (Cheson 1999).

Time frame:
Approximately 3.5 years

No measurements were reported for this outcome.

SecondaryStage 2: Duration of Response (DoR)

Length of time of overall response (Complete Response + Complete Response unconfirmed + Partial Response) based on the International Lymphoma Workshop Response Criteria \[IWRC\] (Cheson 1999).

Time frame:
Approximately 3.5 years

No measurements were reported for this outcome.

SecondaryStage 2: Overall Survival (OS)

Overall survival was defined as time from randomization until death of any cause.

Time frame:
Approximately 3.5 years

No measurements were reported for this outcome.

Other pre-specifiedStage 2: Progression-Free Survival

Number of participants who survive without progressing based on the International Working Group Response Criteria \[IWG\].

Time frame:
Approximately 3.5 years

No measurements were reported for this outcome.

SecondaryStage 2: Duration of Complete Response

Length of time of complete response (Complete Response + Complete Response unconfirmed) based on the International Lymphoma Workshop Response Criteria \[IWRC\] (Cheson 1999).

Time frame:
Approximately 3.5 years

No measurements were reported for this outcome.

SecondaryStage 2: Overall Response Rate for With a Duration of Response Lasting ≥ 16 Weeks

Complete Response + Complete Response unconfirmed + Partial Response for participants with a duration of response lasting ≥ 16 weeks based on the International Lymphoma Workshop Response Criteria \[IWRC\] (Cheson 1999).

Time frame:
Approximately 3.5 years

No measurements were reported for this outcome.

SecondaryStage 2: Time to Progression

Length of time until disease progression occurs

Time frame:
Approximately 3.5 years

No measurements were reported for this outcome.

SecondaryStage 2: Health Related Quality of Life Questionnaires

Quality of Life based on the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and the EQ-5D assessments

Time frame:
Approximately 3.5 years

No measurements were reported for this outcome.

Adverse events

Collected over From first dose of study drug to the final data cut-off date of 18 May 2018; the median study duration of 27.0 and 19.7 weeks, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide48/54 (88.9%)31/54 (57.4%)53/54 (98.1%)
Investigator's Choice51/55 (92.7%)42/55 (76.4%)52/55 (94.5%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventLenalidomideInvestigator's Choice
DIFFUSE LARGE B-CELL LYMPHOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)4/5410/55
ANAEMIABlood and lymphatic system disorders4/543/55
FEBRILE NEUTROPENIABlood and lymphatic system disorders4/542/55
CELLULITISInfections and infestations0/544/55
PNEUMONIAInfections and infestations3/543/55
THROMBOCYTOPENIABlood and lymphatic system disorders1/543/55
VOMITINGGastrointestinal disorders0/543/55
HYPERCALCAEMIAMetabolism and nutrition disorders1/543/55
PYREXIAGeneral disorders2/542/55
URINARY TRACT INFECTIONInfections and infestations2/540/55
Most frequent other events
Showing 10 of 74
Most frequent other events
EventLenalidomideInvestigator's Choice
ANAEMIABlood and lymphatic system disorders17/5431/55
NEUTROPENIABlood and lymphatic system disorders23/5418/55
NAUSEAGastrointestinal disorders10/5423/55
FATIGUEGeneral disorders19/5416/55
DIARRHOEAGastrointestinal disorders18/5416/55
PYREXIAGeneral disorders16/5418/55
THROMBOCYTOPENIABlood and lymphatic system disorders13/5417/55
CONSTIPATIONGastrointestinal disorders16/5416/55
DECREASED APPETITEMetabolism and nutrition disorders8/5415/55
COUGHRespiratory, thoracic and mediastinal disorders13/5410/55

Baseline characteristics

Modified Intent to Treat (mITT) = all study participants randomized with a diffuse large B-cell lymphoma (DLBCL) diagnosis and germinal center B-cell (GCB)/non-germinal center B (non-GCB) subtype confirmed by central pathology, and who received at least one dose of study drug (lenalidomide or Investigator's choice). Nine participants were excluded.

Age, Continuous
Age, Continuous(years)LenalidomideInvestigators Choice (IC)Total
Mean64.7 ± 13.4362.8 ± 13.9463.75 ± 13.69
Sex: Female, Male
Sex: Female, Male(Participants)LenalidomideInvestigators Choice (IC)Total
Female212041
Male303161
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LenalidomideInvestigators Choice (IC)Total
Asian112
Black/African American011
White383674
Missing91120
Other (Unspecified)325
Eastern Cooperative Oncology Performance Status (ECOG)]
Eastern Cooperative Oncology Performance Status (ECOG)](Participants)LenalidomideInvestigators Choice (IC)Total
0 = (Fully Active)181533
1 (Restrictive but Ambulatory)242852
2 (Ambulatory but Unable to Work)7815
3 (Limited Self-Care)000
4 (Completely Disabled)101
Missing101
Creatinine Clearance (CrCl)
Creatinine Clearance (CrCl)(Participants)LenalidomideInvestigators Choice (IC)Total
≥ 60 mL/min324375
≥ 30 but < 60 mL/min18725
Missing112
Disease Stage of DLBCL at Enrollment
Disease Stage of DLBCL at Enrollment(Participants)LenalidomideInvestigators Choice (IC)Total
IA134
IB101
IIA8715
IIB314
IIIA131326
IIIB246
IVA171431
IVB6915
Diffuse Large B-Cell Lymphoma (DLBCL) Subtypes - Germinal Center B-Cell (GCB) and non-GCB
Diffuse Large B-Cell Lymphoma (DLBCL) Subtypes - Germinal Center B-Cell (GCB) and non-GCB(Participants)LenalidomideInvestigators Choice (IC)Total
Germinal Center B-Cell Type232548
Non-Germinal Center B-Cell Type282654
08

Study locations

57 sites
  • Providence St Joseph Medical Center/Cancer Center
    Burbank, California 91505, United States
  • MD Anderson Cancer Center Orlando
    Orlando, Florida 32806, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • University of Michigan, Comprehensive Cancer Center
    Ann Arbor, Michigan 48105, United States
  • Hattiesburg Clinic
    Hattiesburg, Mississippi 39402, United States
  • Washington University Siteman Cancer Center
    Saint Louis, Missouri 63110, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Avera Cancer Institute
    Sioux Falls, South Dakota 57105, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • MD Anderson Houston
    Houston, Texas 77030, United States
  • Royal Adelaide Hospital
    Adelaide, 5000, Australia
  • Royal Brisbaine and Womens Hospital
    Herston, 4029, Australia
  • Princess Alexandra Hospital
    Woolloongabba, 4102, Australia
  • Innsbruck University Hospital
    Innsbruck, A6020, Austria
  • Universitätsklinikum Salzburg
    Salzburg, A-5020, Austria
  • Medical University of Vienna
    Vienna, A-1090, Austria
  • University Hospital Hradec Kralove
    Hradec Kralove 5, 5005, Czechia
  • Charles University
    Praha, 12808, Czechia
  • ICH CHU Brest- C.H.U. MORAVAN
    Brest Cedex 2, 29609, France
  • CHU de Grenoble-Hopital Albert Michallon
    Grenoble, 38043, France
  • Chd -Vendee
    La Roche Sur Yon, 85205, France
  • Centre Hospitalier Lyon Sud
    Lyon, 69495, France
  • Institute Paoli-Calmette
    Marsielle, 13009, France
  • Hotel Dieu
    Nantes Cedex 1, 44903, France
  • Hôpital Saint Jean
    Perpignan, 66046, France
  • CHRU-Hopital du Haut -Leveque
    Pessac, 33604, France
  • CHU de Rennes Hopital de Pontchaillou
    Rennes, 35033, France
  • University Hospital OF Toulouse Purpan
    Toulouse, 31059, France
  • Hopital de Brabois Adultes
    Vandoeuvre-les Nancy cedex, 54511, France
  • Istituto di Ematologica Istituto di Ematologica " L.e. A. Seragnoli' Azienda Ospedaliera Universitaria Policlinico
    Bologna, 40138, Italy
  • Azienda Ospedaliera Universitaria Careggi
    Firenze, 50141, Italy
  • Clinica Ematologica, A.O.U. San Martino di Genova
    Genova, 16132, Italy
  • IEO istituto Europeo di Oncologia
    Miano, 201401, Italy
  • Universita Federico II di Napoli Nuovo Policlinico
    Napoli, 80131, Italy
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Irccs/Crob
    Rionero In Vulture (PZ), 85208, Italy
  • Policlinico Tor Vergata (Universta Tor Vergata)
    Roma, 00133, Italy
  • Azienda Ospedaliera di Perugai Ospedale S. Maria della Miseri
    Terni, 6156, Italy
  • Hospital Universitari Vll D' Hebron
    Barcelona, 8035, Spain
  • Hospital Universitario Reina Sofia
    Cordoba, 14004, Spain
  • Hospital Costa Del Sol
    Marbella, 29600, Spain
  • CH de Orense
    Ourense, 32005, Spain
  • Complejo Hospitalario de Navarra
    Pamplona, 31008, Spain
  • Hosptial Clinico Universitario de Salamanca
    Salamanca, 37007, Spain
  • Onkologiska kliniken
    Umea, 90185, Sweden
  • Akademiska Sjukhuset
    Uppsala, 75185, Sweden
  • Royal Bournemouth Hospital Haematology
    Bournemouth, BH7 7DW, United Kingdom
  • Royal Devon and Exeter Hospital Haematology Department
    Exeter, EX2 5DW, United Kingdom
  • St. James Institute of Oncology
    Leeds, LS9 7TF, United Kingdom
  • Royal Mardsen Hospital - Fulham (Satellite Site)
    London, SW3 6U, United Kingdom
  • The Christie Foundation Trust, I'st Floor, Haemotology Oncology Outpatients, Lymphoma Team
    Manchester, M20 4BX, United Kingdom
  • Derrford Hospital
    Plymouth, PL6 8DH, United Kingdom
  • Southhampton University Hospital NHS Trust
    Southhampton, SO16 6YD, United Kingdom
  • Royal Mardsen NHS Foundation Trust
    Sutton, SM2 SPT, United Kingdom
09

References and documents

Publications

  • Czuczman MS, Trneny M, Davies A, Rule S, Linton KM, Wagner-Johnston N, Gascoyne RD, Slack GW, Brousset P, Eberhard DA, Hernandez-Ilizaliturri FJ, Salles G, Witzig TE, Zinzani PL, Wright GW, Staudt LM, Yang Y, Williams PM, Lih CJ, Russo J, Thakurta A, Hagner P, Fustier P, Song D, Lewis ID. A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clin Cancer Res. 2017 Aug 1;23(15):4127-4137. doi: 10.1158/1078-0432.CCR-16-2818. Epub 2017 Apr 5. PubMed 28381416 ↗
  • Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, Goy A, Witzig TE, Czuczman MS. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011 Nov 15;117(22):5058-66. doi: 10.1002/cncr.26135. Epub 2011 Apr 14. PubMed 21495023 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2010 to primary completion in Jul 2013, 34 months.

Results were first posted in Aug 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2010
First posted
Sep 9, 2010
StartActual
Sep 2, 2010
Primary completionActual
Jul 4, 2013
CompletionActual
Apr 5, 2018
Results first posted
Aug 20, 2014
Last update
Nov 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01197560
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Sep 9, 2010
Start date
Sep 2, 2010
Primary completion
Jul 4, 2013
Completion
Apr 5, 2018
Results posted
Aug 20, 2014
Last update
Nov 25, 2019

Study contacts

Adrian Kilcoyne, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion